New treatment for patients with multiple myeloma

A new treatment option has been included in the list of compensated medicines for patients with multiple myeloma who have recovered after a previous treatment course. Access to the new 100% compensated treatment option means for patients suffering from multiple myeloma, an incurable and difficult to treat disease, a chance at a time without disease progression and the fact that they can again enjoy a quality . With each new treatment available, the patient wins time, months or years of life, a period when innovative treatments now in research may be available and life expectancy increases. The new therapeutic option was included on the list of 100% offset medications following the update of the list of compensated and free medicines since the end of September. The treatment will be provided on the basis of a cost-volume contract between the producing company and the National Health Insurance House. Therapy received the status of orphan drug from the European Medicines Agency in 2008 and was approved in an accelerated procedure by the agency in 2015.

The treatment was approved in combination with another molecule for the treatment of adult patients with multiple myeloma who received at least one previous therapy. The new treatment option prolongs the patient's life without disease progression. If 15 years ago the median survival of patients with multiple myeloma was 3 years, it now reaches 6-8 years. Dr. .

Daniel Coriu, Director of the Center for Hematology and Bone Transplantation, Fundeni Clinical Institute. Multiple myeloma is an incurable, rare, and very aggressive form of blood cancer that affects the bone marrow. Multiple myeloma is the second disease of frequency in terms of blood cancer. Each year, they are diagnosed with multiple myeloma approximately 39. 000 patients across Europe and reported 24.000 deaths. Approximately 37% of those diagnosed are less than 65 years of age. The most common symptoms of multiple myeloma are severe back pains repeated infections anemia renal failure fractures or compression of vertebrae The disease is complex and is characterized by periods of remission followed by relapse, which means it returns to a much more aggressive form. Over time, multiple myeloma progresses, periods of time under control are shortened, complications multiply, quality of life decreases, and illness affects the patient's life in all its physical, mental, social and family aspects. .